Impact of TP53 Mutations on Survival in Large B-Cell Lymphoma Patients

Rui Liu's dataset contains survival outcomes for 195 adult patients with relapsed/refractory large B-cell lymphoma, analyzed to compare the impact of TP53 mutations between CAR-T cell therapy and chemotherapy-based treatments. The data includes results from Next-Generation Sequencing (NGS) for 75 TP53-mutated patients and treatment response assessments per Lugano 2014 criteria. It was last updated on June 3, 2026.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) between TP53-mutated and wild-type patients based on the described Kaplan-Meier analysis.
• Analyze objective response rates to CAR-T therapy versus chemotherapy based on the reported 56.6% vs 18.2% rates for TP53-mutated patients.
• Investigate the association between TP53 mutation type (missense vs. disruptive) and protein domain (DBD vs. non-DBD) with patient outcomes.
• Assess the incidence of CAR-T-related toxicities, such as cytokine release syndrome, across different TP53 mutation statuses.

Strengths

• Includes specific patient cohort sizes: 195 total patients, with 75 (38%) identified as TP53-mutated.
• Reports concrete survival metrics, such as a median OS of 12.13 months for TP53-mutated patients receiving CAR-T therapy.
• Compares two distinct treatment modalities: 151 patients received CAR-T therapy and 44 received non-CAR-T chemotherapy.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or institutional bias inherent to the retrospective, single-study design described.

Provenance

Source

Rui Liu via figshare.

Collection Method

Retrospective analysis of 195 adult patients with r/r LBCL who underwent Next-Generation Sequencing (NGS).

Freshness

Last updated 2026-06-03 06:06:55; freshness should be verified.